| Literature DB >> 35070052 |
Renato Patrone1, Francesco Izzo2, Raffaele Palaia2, Vincenza Granata3, Guglielmo Nasti4, Alessandro Ottaiano4, Gilda Pasta5, Andrea Belli6.
Abstract
BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer and is characterized by an aggressive behavior and a dismal prognosis. Radical surgical resection represents the only potentially curative treatment. Despite the increasing acceptance of laparoscopic liver resection for surgical treatment of malignant liver diseases, its use for ICC is not commonly performed. In fact, to achieve surgical free margins a major resection and/or vascular and/or biliary reconstructions is often needed, as well as an associated lymph node dissection. AIM: To review and summarize the current evidences on the minimally invasive resection of ICC.Entities:
Keywords: Biliary neoplasm; Cholangiocarcinoma; Hepatectomy; Laparoscopic; Liver resection; Minimally invasive
Year: 2021 PMID: 35070052 PMCID: PMC8713325 DOI: 10.4251/wjgo.v13.i12.2203
Source DB: PubMed Journal: World J Gastrointest Oncol
Figure 1PRISMA flow-chart. Figure reported the diagram of our systematic review of the literature, performed in 4 databases from Jan 1, 2009 up to Jan 1, 2021. Search terms included: "cholangiocarcinoma", "intrahepatic", "laparoscopic", "surgery", "minimally invasive", "robotic surgery" "biliary neoplasm", "liver resection" and "hepatectomy". Inclusion criteria are in the big circle-box. Major reasons for exclusion were the absence of patients treated both with laparoscopic and open approach (n = 114) and the inclusion of other tumor types besides intrahepatic cholangiocarcinoma (n = 36). Further reasons for exclusion were population treated with palliative intent or case series or absence of specific data on the post-operative outcomes. This led to the final selection of 9 studies which fulfilled the inclusion criteria. ICC: Intrahepatic cholangiocarcinoma.
Study characteristics and quality assessment
|
|
|
|
|
|
|
| |||
|
|
|
| |||||||
| Wu | China | RetS-SC | Case control study | 18 | 25 |
|
|
| 17 |
| Haber | Germany | RetS-SC | Case control study | 27 | 31 | *** | * | ** | 16 |
| Kang | Korea | RetS-SC | Propensity score matching | 30 | 61 | *** | ** | *** | 18 |
| Kinoshita | Japan | RetS-SC | Case control study | 15 | 21 | *** | ** | *** | 18 |
| Ratti | United Kingdom-Italy | RetS-TC | Propensity score matching | 104 | 104 | *** | ** | *** | 19 |
| Martin | United States | RetS-DB | Database | 312 | 1997 | ** | * | ** | 15 |
| Zhu | China | RetS-SC | Propensity score matching | 20 | 63 | *** | ** | *** | 19 |
| Wei | China | RetS-SC | Case control study | 30 | 20 | *** | ** | *** | 19 |
| Lee | Korea | RetS-SC | Case control study | 14 | 23 | *** | ** | *** | 20 |
LS: Number of patients treated with laparoscopic surgery; OS: Number of patients treated with open surgery; NOS: Newcastle-Ottawa Scale for assessing the quality of nonrandomised studies.A study can be awarded a maximum of one star (*) for each numbered item within the selection and exposure categories. A maximum of two stars can be given for comparability. MINORS: Methodological index for non-randomized studies; RetS: Retrospective study; SC: Single center; TC: Two centres; DB: Data base.
Preoperative and surgical data
| Ref. | SA | NP | AGE | ASA | MayorH | Lymphadenectomy | OT | IOBL | CONV. | ||||
|
|
|
|
|
|
| ||||||||
| Wu | OS | 25 | 61 | 19 | 6 | 13 (52%) | 6 (32%) | 6 | 300 (257-392) |
| N/A | ||
| LS | 18 | 64 | 15 | 3 | 6 (33%) | 8 (33%) | 6 | 305 (207-390) |
| 0 | |||
| Haber | OS | 31 | 63 | 1 | 21 | 8 | 1 | 24 (78%) | 29 (94%) | 8 | 282 (112–947) | / | N/A |
| LS | 27 | 69 | 0 | 15 | 12 | 0 | 19 (70%) | 23 (85%) | 8 | 314 (125–439) | / | 2 | |
| Kang | OS | 61 | 68 | / | / | / | / |
|
| / | 343.2 ± 106.0 | 979.3 ± 864.4 | N/A |
| LS | 30 | 65 | / | / | / | / |
|
| / | 375.2 ± 204.0 | 1396.7 ± 2568.9 | 6 | |
| Kinoshita | OS | 21 | 68 | / | / | / | / | 15 | 7 (33%) | 3 | 358 (150-634) |
| N/A |
| LS | 15 | 65 | / | / | / | / | 5 | 6 (40%) | 2 | 360 (221-802) |
| 0 | |
| Ratti | OS | 209 | 62 | 20 | 58 | 26 | 0 | 38 (36.5%) |
| 7 (5–14) | 230 ± 60 |
| N/A |
| LS | 114 | 60 | 22 | 56 | 26 | 0 | 35 (33.7%) |
| 8 (5–11) | 270 ± 65 |
| 0 | |
| Martin | OS | 1997 | 64 | / | / | / | / |
|
| / | / | / | N/A |
| LS | 312 | 65 | / | / | / | / |
|
| / | / | / | / | |
| Zhu | OS | 63 | 56 | / | / | / | / | 43 (68.3%) | 27 (42.9%) | / |
| 400 (50–2000) | N/A |
| LS | 20 | 54 | / | / | / | / | 11 (55%) | 8 (40%) | / |
| 200 (50–1000) | 2 | |
| Wei | OS | 20 | 60.5 | / | / | / | / | 11 (55%) | 11 (55%) | / | 230 (125–420) | 350 (50–1200) | N/A |
| LS | 12 | 61.5 | / | / | / | / | 7 (58.3%) | 4 (33%) | / | 212.5 (60–500) | 350 (30–2000) | 0 | |
| Lee | OS | 23 | 59 | 0 | 20 | 2 | 1 |
| 15 (65.2%) | 6 (1–16) | 330.0 (140–590) |
| N/A |
| LS | 14 | 66 | 0 | 12 | 2 | 0 |
| 5 (35.7%) | 4 (1–12) | 255.0 (140–480) |
| 0 | |
Results for each Author are represented divided in two lines: Open surgery and laparoscopic surgery. LS: Laparoscopic surgery; OS: Open surgery; SA: Surgical approach; NP: Number of patients; Age are expressed in year; ASA: American Society of Anaesthesiologists physical status classification; MajorH: Major hepatectomy considered as equal or more than 3 resected segments; OT: Operation time expressed in minutes; IOBL: Intra-operative blood loss expressed in mL; Conv: Number of procedure converted from laparoscopic to open approach. In bold differences with a P value < 0.05.
Post-operative and oncological data
| Ref. | SA | ICUS | HS | HM | 30-d morbidity | 90-d morbidity | mFU | OS | DFS | ||
|
|
|
|
| ||||||||
| Wu | OS | / |
| / | / | 23 | 2 | 1 | / | 20 | 4 |
| LS | / |
| / | / | 17 | 1 | 0 | / | 47.1 | 0 | |
| Haber | OS | 1 (0–6) |
| 23 | 8 |
|
| 0 | / | / | / |
| LS | 1 (0–81) |
| 24 | 3 |
|
| 2 | / | / | / | |
| Kang | OS | / |
| / | / | / | 23 | 0 | 16.8 | 81.2 | 42.5 |
| LS | / |
| / | / | / | 8 | 0 | 39.2 | 76.7 | 65.6 | |
| Kinoshita | OS | / | / | 20 | 1 | / | 4 | / | / | 36 | 19 |
| LS | / | / | 14 | 1 | / | 2 | / | / | 32 | 24 | |
| Ratti | OS | 4 (3–10) |
| 99 | 5 | 17 | 8 | 2 | 50 | 47 | 34 |
| LS | 3 (1–5) |
| 101 | 3 | 11 | 4 | 1 | 39 | 46 | 36 | |
| Martin | OS | / | / | 1451 | 546 | / | / | / | / | / | / |
| LS | / | / | 247 | 65 | / | / | / | / | / | / | |
| Zhu | OS | / | 7 (3–33) | 58 | 5 | 22 | 6 | 0 | 24 | 17 | 32 |
| LS | / | 6 (3–9) | 19 | 1 | 3 | 1 | 0 | 24 | 21 | 31 | |
| Wei | OS | / | 11 (5–30) | 19 | 2 | 10 | 3 | 0 | 12 | 32.7 | 27.9 |
| LS | / | 14 (6–23) | 12 | 0 | 3 | 2 | 0 | 17.5 | 56.3 | 43.8 | |
| Lee | OS | / | 20 (9–63) | / | / | 1 | 4 | 0 | / | 75.7 | / |
| LS | / | 15 (9–29) | / | / | 0 | 3 | 0 | / | 84.6 | / | |
Results for each Author are represented divided in two lines: Open surgery and laparoscopic surgery. LS: Laparoscopic surgery; OS: Open surgery; SA: Surgical approach; ICUS: Intensive care unit stay in days; HS: Hospital stay in days; HM: Histopathological margins; mFU: Median follow-up in months; OS: Overall survival expressed in months after surgery; DFS: Disease-free survival expressed in months after surgery. In bold differences with a P value < 0.05.